Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
3Customers
2Debt Items
11Related Chains
Source-Backed Evidence Depth
LB Pharmaceuticals Inc (LBRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
3Distinct source URLs
11High confidence
0.822Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
LB Pharmaceuticals Inc Suppliers
Ticker
Name
Confidence
Evidence
EXTERNAL-VENDORS-AND-CROS
EXTERNAL-VENDORS-AND-CROS
90%
This model includes internal teams and systems as well as external vendors and CROs to comprise a full clinical trial team.
THIRD-PARTIES
THIRD-PARTIES
85%
We also rely on third parties to provide other products, services, parts, or otherwise to operate our business, including with respect to our cybersecurity infrastructure.
ANDREW-VAINO
ANDREW-VAINO
80%
In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
ANDREW-VAINO-PH-D
ANDREW-VAINO-PH-D
80%
In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
MARC-PANOFF
MARC-PANOFF
80%
In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
ZACHARY-PRENSKY
ZACHARY-PRENSKY
80%
In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
Reciprocal relationship from NBP graph: rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our produ…
LB Pharmaceuticals Inc Customers
Ticker
Name
Confidence
Evidence
LICENSEES-OF-LB-102
LICENSEES-OF-LB-102
90%
Net sales are defined in these agreements as the gross payments received on total commercial sales of LB-102 less certain standard deductions, whether received by us or any licensee of LB-102.
HOLDERS-OF-FUTURE-ROYALTIES
HOLDERS-OF-FUTURE-ROYALTIES
80%
As of March 31, 2026, certain of our former and current officers and their affiliates held 1.13% of the future royalties.
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
the stock option grants. The comparable companies were chosen based on their size, stage of their life cycle, or area of specialty. We will continue to apply this process until enough historical info…
LB Pharmaceuticals Inc Debt Obligations
Instrument
Description
Confidence
Evidence
LBRX-DEBT-10624
Warrants outstanding: 247000
90%
xbrl warrant detail from xbrl 2025-12-31.
LBRX-DEBT
Debt stack $3.5M
90%
Market cache reports total debt of $3.5M.
LB Pharmaceuticals Inc Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for LB Pharmaceuticals Inc.
LB Pharmaceuticals Inc Ownership
Holder
Name
Confidence
Evidence
LBRX-OWNER-DEEP-TRACK-CAPITAL-LP
Deep Track Capital, LP
90%
13F overlay lists Deep Track Capital, LP as top holder; 77 tracked holders.
